CL2018003050A1 - Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. - Google Patents

Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas.

Info

Publication number
CL2018003050A1
CL2018003050A1 CL2018003050A CL2018003050A CL2018003050A1 CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1 CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A CL2018003050 A CL 2018003050A CL 2018003050 A1 CL2018003050 A1 CL 2018003050A1
Authority
CL
Chile
Prior art keywords
treatment
angle
wnt
disorders
signaling
Prior art date
Application number
CL2018003050A
Other languages
English (en)
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Joseph Timothy Marakovits
Chandramouli Chiruta
Chi Ching Mak
Jianguo Cao
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of CL2018003050A1 publication Critical patent/CL2018003050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DIVULGAN COMPUESTOS DE ISOQUINOLINA PARA EL TRATAMIENTO DE DIVERSAS ENFERMEDADES Y PATOLOGÍAS. MÁS CONCRETAMENTE, LA PRESENTE DIVULGACIÓN SE REFIERE AL USO DE UN COMPUESTO DE ISOQUINOLINA, O ANÁLOGOS DE LA MISMA, EN EL TRATAMIENTO DE TRASTORNOS CARACTERIZADOS POR LA ACTIVACIÓN DE LA SEÑALIZACIÓN DE LA VÍA WNT (POR EJEMPLO, CÁNCER, PROLIFERACIÓN CELULAR ANORMAL, ANGIOGÉNESIS, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD PULMONAR, INFLAMACIÓN, ENFERMEDADES AUTOINMUNITARIAS Y ARTROSIS), LA MODULACIÓN DE LOS EVENTOS CELULARES MEDIADOS POR LA SEÑALIZACIÓN DE LA VÍA WNT, ASÍ COMO LAS AFECCIONES/LOS TRASTORNOS/LAS ENFERMEDADES NEUROLÓGICOS RELACIONADOS CON LA SOBREEXPRESIÓN DE DYRK1A.
CL2018003050A 2016-04-27 2018-10-26 Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. CL2018003050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27

Publications (1)

Publication Number Publication Date
CL2018003050A1 true CL2018003050A1 (es) 2019-01-25

Family

ID=60157342

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003050A CL2018003050A1 (es) 2016-04-27 2018-10-26 Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas.
CL2019002067A CL2019002067A1 (es) 2016-04-27 2019-07-24 Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002067A CL2019002067A1 (es) 2016-04-27 2019-07-24 Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas. (divisional solicitud 201803050).

Country Status (19)

Country Link
US (5) US10508099B2 (es)
EP (2) EP3943086A1 (es)
JP (1) JP7023243B2 (es)
KR (1) KR102399206B1 (es)
CN (1) CN109311819B (es)
AR (1) AR108326A1 (es)
AU (1) AU2017258187B2 (es)
BR (1) BR112018072190A2 (es)
CA (1) CA3022044A1 (es)
CL (2) CL2018003050A1 (es)
CO (1) CO2018012655A2 (es)
IL (1) IL262495B (es)
MA (1) MA43605B1 (es)
MX (1) MX386319B (es)
PE (1) PE20190260A1 (es)
PH (1) PH12018502259A1 (es)
RU (1) RU2018141379A (es)
SG (2) SG10201914127PA (es)
WO (1) WO2017189823A2 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975068B2 (en) 2016-04-27 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl thiazoles as modulators of RORγT
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EP3601259B1 (en) 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
AU2018352828A1 (en) * 2017-10-17 2020-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019084497A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019084496A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
KR20220058553A (ko) * 2019-09-05 2022-05-09 루난 파마슈티컬 그룹 코퍼레이션 Magl 억제제 및 이의 제조 방법, 용도
WO2021257977A1 (en) * 2020-06-19 2021-12-23 Vanderbilt University Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor m5 inhibitors
EP4236950A4 (en) * 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP4294798A1 (en) * 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP2024545132A (ja) * 2021-12-10 2024-12-05 プロシーナ バイオサイエンシーズ リミテッド Ｄｙｒｋ１ａ阻害剤としての複素環化合物
TW202506660A (zh) * 2023-04-27 2025-02-16 美商塞普特納公司 Mrgprx2拮抗劑及其使用方法
KR102929140B1 (ko) 2023-05-09 2026-02-24 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US8088793B2 (en) * 2007-08-15 2012-01-03 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
CN105037355B (zh) * 2009-08-10 2017-06-06 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
RU2012146246A (ru) * 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
EA026115B1 (ru) 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
IN2014CN02646A (es) * 2011-09-14 2015-08-07 Samumed Llc
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3813826A4 (en) 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975068B2 (en) 2016-04-27 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl thiazoles as modulators of RORγT
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT

Also Published As

Publication number Publication date
KR102399206B1 (ko) 2022-05-17
US20200339536A1 (en) 2020-10-29
IL262495B (en) 2021-12-01
US10556885B2 (en) 2020-02-11
IL262495A (en) 2018-12-31
KR20190012167A (ko) 2019-02-08
EP3943086A1 (en) 2022-01-26
SG11201809310PA (en) 2018-11-29
MA43605B1 (fr) 2020-10-28
RU2018141379A (ru) 2020-05-28
AR108326A1 (es) 2018-08-08
US20230104155A1 (en) 2023-04-06
EP3448838B1 (en) 2021-08-11
US10508099B2 (en) 2019-12-17
WO2017189823A3 (en) 2018-02-08
JP7023243B2 (ja) 2022-02-21
MX2018013173A (es) 2019-02-13
PE20190260A1 (es) 2019-02-25
CN109311819A (zh) 2019-02-05
US20180208580A1 (en) 2018-07-26
CO2018012655A2 (es) 2019-04-30
EP3448838A2 (en) 2019-03-06
CN109311819B (zh) 2022-10-25
JP2019515931A (ja) 2019-06-13
MX386319B (es) 2025-03-18
WO2017189823A2 (en) 2017-11-02
PH12018502259A1 (en) 2019-06-10
EP3448838A4 (en) 2019-12-25
RU2018141379A3 (es) 2020-08-13
SG10201914127PA (en) 2020-02-27
AU2017258187B2 (en) 2021-08-26
CA3022044A1 (en) 2017-11-02
US20180222887A1 (en) 2018-08-09
US11673881B2 (en) 2023-06-13
AU2017258187A1 (en) 2018-11-15
US11174244B2 (en) 2021-11-16
BR112018072190A2 (pt) 2019-02-12
US10287267B2 (en) 2019-05-14
CL2019002067A1 (es) 2020-07-10
US20170313681A1 (en) 2017-11-02
MA43605A1 (fr) 2020-04-30

Similar Documents

Publication Publication Date Title
CL2018003050A1 (es) Isoquinolin-3-il-carboxamidas, y preparación y uso de las mismas.
CL2019001343A1 (es) Isoquinolin-3-il-carboxamidas y preparación y uso de las mismas. (divisional solicitud 201803065)
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018002794A1 (es) Compuestos bicíclicos
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
UY37958A (es) Moduladores de la vía de estrés integrada
MX2018013495A (es) Moduladores de la via de estres integrada.
BR112018003634A8 (pt) Processo para preparar um inibidor parp, formas cristalinas e usos destes
UY35628A (es) ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
MX379228B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
UY35023A (es) Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
MX2017014774A (es) Composiciones farmaceuticas de levetiracetam de liberacion extendida.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2020002177A1 (es) Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas
CR20160133A (es) Derivados de fenilalanina sustituidos
MX378739B (es) Compuestos de 2-oxindol.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.